However, this outcome fell short of the anticipated 25% weight reduction, potentially limiting its competitive edge against Eli Lillys ZEPBOUND, which reported up to 20.9% weight loss in the SURMOUNT-1 trial. In the subsequent REDEFINE 2 trial, which focused on adults with obesity or overweight and type 2 diabetes, CagriSema achieved a 15.7% mean weight loss after 68 weeks, compared to 3.1% with placebo
Exome sequencing for bipolar disorder points to roles of de novo loss-of-function and protein-altering mutations
P.AngelmaryA.KadalmaniB
At its core, this regulatory escalation is the inevitable result of long-running friction between Hims and major drugmakers
Malik, M., Mendoza, M., Payson, M
According to Growth Market Reports, the cold-chain biologics market is projected to reach about $39.1 billion by 2033, growing at a compound annual rate of 8.3%